IRB #

STUDY00015304

Title

CC #144525: Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma

Principal Investigator

Charles Lopez

Study Purpose

To assess the safety of Ibrutinib (study drug) in combination with Gemcitabine and Nab-Paclitaxel in adults with metastatic pancreatic adenocarcinoma

Medical Condition(s)

Metastatic Pancreatic Adenocarcinoma

Eligibility Criteria

1. Male or female age 18 or older
2. Confirmed pancreatic adenocarcinoma
3. Metastatic disease
4. No prior systemic therapy for metastatic disease


Other criteria apply

Age Range

18 - 180

Healthy Volunteers Needed

No

Duration of Participation

Treatment will continue until your disease progresses, you can’t tolerate the treatment, or you and/or your doctor decide to stop treatment. After that participants will be followed for one year until the end of the study.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080
knight@ohsu.edu

Sponsor

Pharmacyclics LLC, an AbbVie Company
Stand Up To Cancer Foundation
University of California, San Francisco

Recruitment End

12/31/2030

Compensation Provided

No


Go Back